S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Low Beta Stocks To Offset A Possible Hard Landing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
5 Cheap Ways to Ride The AI Supercycle to Profits
Nursing Home REITs: The Surprise Heroes of High Yield Investing
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 Intriguing ETFs Trading Under $10 a Share
Energy Stocks Shine as High Oil Prices Boost Dividend Yields

Larimar Therapeutics (LRMR) Stock Forecast, Price & News

$4.36
-0.13 (-2.90%)
(As of 09/28/2023 ET)
Compare
Today's Range
$4.34
$4.49
50-Day Range
$3.11
$4.49
52-Week Range
$2.58
$6.85
Volume
107,185 shs
Average Volume
129,770 shs
Market Capitalization
$188.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.83

Larimar Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
171.4% Upside
$11.83 Price Target
Short Interest
Healthy
1.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.81) to ($0.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

396th out of 969 stocks

Pharmaceutical Preparations Industry

171st out of 453 stocks


LRMR stock logo

About Larimar Therapeutics (NASDAQ:LRMR) Stock

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

LRMR Price History

LRMR Stock News Headlines

Larimar Therapeutics (LRMR) Receives a Buy from JMP Securities
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
Surprising "Twist" Hands Biden Landslide Re-election?
This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.
Larimar Therapeutics to join Russell 3000 Index
Where Larimar Therapeutics Stands With Analysts
See More Headlines
Receive LRMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LRMR Company Calendar

Last Earnings
8/10/2023
Today
9/28/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LRMR
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.83
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+171.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-35,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.56 per share

Miscellaneous

Free Float
41,417,000
Market Cap
$188.70 million
Optionable
Not Optionable
Beta
0.50
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Carole S. Ben-Maimon M.D. (Age 64)
    CEO, Pres & Director
    Comp: $845.63k
  • Mr. Michael Celano CPA (Age 64)
    Sec. & CFO
    Comp: $562.62k
  • Mr. John Berman
    VP of Fin. & Admin.
  • Ms. Jennifer Spokes Johansson
    VP of Regulatory, Quality & Legal
  • Dr. Russell G. Clayton Sr. (Age 62)
    D.O, Chief Medical Officer
  • Dr. Gopi Shankar M.B.A. (Age 52)
    Ph.D., Chief Devel. Officer
  • Mr. Francis Michael Conway CPA
    VP & Controller













LRMR Stock - Frequently Asked Questions

Should I buy or sell Larimar Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LRMR shares.
View LRMR analyst ratings
or view top-rated stocks.

What is Larimar Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued 1 year target prices for Larimar Therapeutics' stock. Their LRMR share price forecasts range from $4.50 to $17.00. On average, they expect the company's stock price to reach $11.83 in the next twelve months. This suggests a possible upside of 171.4% from the stock's current price.
View analysts price targets for LRMR
or view top-rated stocks among Wall Street analysts.

How have LRMR shares performed in 2023?

Larimar Therapeutics' stock was trading at $4.13 at the beginning of the year. Since then, LRMR stock has increased by 5.6% and is now trading at $4.36.
View the best growth stocks for 2023 here
.

When is Larimar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our LRMR earnings forecast
.

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02.

What is Larimar Therapeutics' stock symbol?

Larimar Therapeutics trades on the NASDAQ under the ticker symbol "LRMR."

Who are Larimar Therapeutics' major shareholders?

Larimar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include CHI Advisors LLC (7.89%), BlackRock Inc. (3.32%), Point72 Asset Management L.P. (1.94%), Geode Capital Management LLC (1.24%), State Street Corp (0.99%) and Dimensional Fund Advisors LP (0.74%). Insiders that own company stock include James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton.
View institutional ownership trends
.

How do I buy shares of Larimar Therapeutics?

Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Larimar Therapeutics' stock price today?

One share of LRMR stock can currently be purchased for approximately $4.36.

How much money does Larimar Therapeutics make?

Larimar Therapeutics (NASDAQ:LRMR) has a market capitalization of $188.70 million. The company earns $-35,350,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How can I contact Larimar Therapeutics?

Larimar Therapeutics' mailing address is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. The official website for the company is larimartx.com. The company can be reached via phone at (844) 511-9056 or via email at investors@larimartx.com.

This page (NASDAQ:LRMR) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -